Public Sector Pension Investment Board lifted its holdings in Globus Medical, Inc. (NYSE:GMED – Free Report) by 329.9% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 253,189 shares of the medical device company’s stock after acquiring an additional 194,296 shares during the period. Public Sector Pension Investment Board owned approximately 0.19% of Globus Medical worth $19,366,000 as of its most recent filing with the SEC.
Other hedge funds have also bought and sold shares of the company. Washington Trust Advisors Inc. grew its stake in Globus Medical by 116.8% during the second quarter. Washington Trust Advisors Inc. now owns 45,006 shares of the medical device company’s stock worth $3,556,000 after purchasing an additional 24,250 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Globus Medical in the second quarter valued at approximately $1,858,000. Illinois Municipal Retirement Fund lifted its stake in Globus Medical by 24.5% in the third quarter. Illinois Municipal Retirement Fund now owns 73,173 shares of the medical device company’s stock valued at $5,481,000 after buying an additional 14,412 shares during the period. Public Employees Retirement System of Ohio acquired a new position in Globus Medical in the second quarter valued at approximately $7,941,000. Finally, Congress Asset Management Co. boosted its holdings in shares of Globus Medical by 6.6% during the 3rd quarter. Congress Asset Management Co. now owns 361,026 shares of the medical device company’s stock worth $27,041,000 after buying an additional 22,401 shares in the last quarter. 95.16% of the stock is owned by institutional investors.
Analysts Set New Price Targets
Several analysts have recently weighed in on GMED shares. Weiss Ratings reiterated a “hold (c+)” rating on shares of Globus Medical in a research note on Friday, October 9th. Zacks Research downgraded shares of Globus Medical from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 9th. Wall Street Zen lowered shares of Globus Medical from a “buy” rating to a “hold” rating in a research note on Saturday, November 7th. BMO Capital Markets downgraded shares of Globus Medical from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $94.00 to $78.00 in a research note on Friday, November 6th. Finally, Needham & Company LLC decreased their price target on shares of Globus Medical from $117.00 to $100.00 and set a “buy” rating for the company in a research note on Friday, November 6th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Globus Medical currently has an average rating of “Moderate Buy” and a consensus target price of $96.08.
Check Out Our Latest Analysis on GMED
Globus Medical Stock Down 2.6%
Shares of GMED opened at $66.79 on Friday. The business’s fifty day moving average is $75.98 and its 200 day moving average is $82.19. Globus Medical, Inc. has a 12-month low of $66.63 and a 12-month high of $101.40. The stock has a market cap of $8.85 billion, a P/E ratio of 16.41, a P/E/G ratio of 1.09 and a beta of 0.98.
Globus Medical (NYSE:GMED – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The medical device company reported $1.23 EPS for the quarter, beating analysts’ consensus estimates of $1.20 by $0.03. Globus Medical had a net margin of 17.76% and a return on equity of 14.43%. The business had revenue of $763.72 million during the quarter, compared to analyst estimates of $792.39 million. During the same quarter in the previous year, the business posted $1.18 EPS. Globus Medical’s quarterly revenue was down .7% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. On average, analysts expect that Globus Medical, Inc. will post 4.98 EPS for the current year.
Insider Activity
In other news, Director Ann Rhoads sold 5,000 shares of the business’s stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $85.00, for a total transaction of $425,000.00. Following the completion of the sale, the director directly owned 35,384 shares of the company’s stock, valued at $3,007,640. The trade was a 12.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director James R. Tobin sold 41,666 shares of the company’s stock in a transaction dated Tuesday, November 10th. The stock was sold at an average price of $75.16, for a total transaction of $3,131,616.56. Following the completion of the sale, the director owned 15,000 shares in the company, valued at $1,127,400. This represents a 73.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 76,666 shares of company stock valued at $5,794,017. 18.38% of the stock is currently owned by insiders.
Globus Medical Company Profile
Globus Medical is a medical device company focused on musculoskeletal care. Its products include implants and instruments used in spine surgery, as well as solutions for orthopedic trauma and other orthopedic procedures. The company also develops surgical technologies, including robotic navigation and imaging systems designed to support planning and guidance during procedures. Its portfolio expanded significantly in 2023 when Globus Medical completed its combination with NuVasive, a provider of spine care products and technologies.
Read More
- Five stocks we like better than Globus Medical
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.
